US 12,011,449 B2
Therapeutic combinations comprising a c-RAF inhibitor
Giordano Caponigro, Foxborough, MA (US); Vesselina Cooke, Newton, MA (US); Matthew John Meyer, Framingham, MA (US); and Darrin Stuart, Marblehead, MA (US)
Assigned to NOVARTIS AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Mar. 3, 2021, as Appl. No. 17/191,205.
Application 17/191,205 is a continuation of application No. 16/332,120, granted, now 10,973,829, previously published as PCT/IB2017/055641, filed on Sep. 18, 2017.
Claims priority of provisional application 62/396,504, filed on Sep. 19, 2016.
Prior Publication US 2022/0008426 A1, Jan. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5377 (2006.01); A61K 31/4965 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/5377 (2013.01) [A61K 31/4965 (2013.01); A61P 35/00 (2018.01)] 8 Claims
OG exemplary drawing
 
1. A method for treating a cancer, selected from BRAF-mutant NSCLC and NSCLC and KRAS-mutant ovarian cancer, in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical combination of: (i) a CRAF inhibitor which is Compound A,

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
and
(ii) an ERK inhibitor which is Compound B,

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.